trial

A Study of Paliperidone Palmitate 6-Month Formulation

NCTId NCT04072575
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 178 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2022-05-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
178 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-09-19
Primary completion
2022-05-03
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
PP6M injection Dose 1PP6M injection Dose 2

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

30 total
Buenos Aires, ArgentinaCórdoba, ArgentinaCórdoba, ArgentinaLa Plata, ArgentinaLa Plata, ArgentinaRosario, ArgentinaHong Kong, Hong KongLecce, ItalyNaples, ItalyRoma, ItalyBialystok, PolandChełmno, Poland

Linked catalysts

1
A Study of Paliperidone Palmitate 6-Month Formulation — primary completion2022-05-03

Facts & assertions

4 sourced
Enrollment
178
Phase
PHASE3
Primary Completion Date
2022-05-03
Status
COMPLETED
relationships
The graph out of here
drug
PP6M injection Dose 1
drug
PP6M injection Dose 2
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication